Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase 2 trials for psoriasis and atopic dermatitis. The company has decided to discontinue development of the drug. Separately, a surprise FDA inspection is underway at Sun Pharma’s Halol manufacturing facility.
Paul Black’s 3 thumb rules for identifying great wealth creators
Veteran portfolio manager Paul Black’s investment framework focuses on identifying businesses with competitive advantages that strengthen over time. His three key rules emphasise widening moats,